Regeneron Q3 2026: Dupixent Drives Growth as a Sanofi Milestone Upside Emerges

REGN, EPS, earnings surprise, EPS consensus, revenue forecast — a compact read on Regeneron’s third quarter and what it could portend for peers in the sector.

Key numbers at a glance

Ticker: REGN (Regeneron Pharmaceuticals, Inc.).
Q3 2026 revenue: $5.1 billion, up 36% year over year.
Dupixent: global net sales $6.5 billion (reported by Sanofi), up 35% year over year.
EYLEA HD: U.S. net sales $699 million, up 62% year over year.
Libtayo: global net sales $550 million, up 51% year over year.
GAAP EPS: $18.45, up 35% year over year.
Non-GAAP EPS: $20.07, up 70% year over year.
Strategic up‑front: Sanofi collaboration expanded with a $1.0 billion up-front; potential up to $7.0 billion in milestones; recognition timing for collaboration revenue in Q4 2026.
Regulatory and pipeline notes: Pasatru (garetosmab) FDA-approved for fibrodysplasia ossificans progressiva (FOP); cemdisiran Phase 3 in generalized myasthenia gravis targeted for a decision next month.

The press release reiterates Regeneron’s blend of commercial strength and pipeline ambition, with a focus on a few big drivers and a long runway of candidates.

Financial highlights and what they imply

Regeneron delivered a solid top-line beat in the sense that revenue grew meaningfully, and earnings per share climbed briskly. The GAAP EPS figure rose 35% to $18.45, while non-GAAP EPS jumped 70% to $20.07, underscoring a mix of higher gross margins, favorable product mix, and operational leverage. In a year where the stock’s multiple often reflects pipeline optionality, these numbers cement the idea that Regeneron can translate strong demand for its core franchises into tangible profit expansion—at least on a per-share basis.

There was no explicit disclosure of an earnings surprise against a published EPS consensus in the release, but the magnitude of the earnings growth paired with robust revenue expansion suggests that management is meeting or exceeding investor expectations on multiple fronts. The company’s narrative remains anchored in Dupixent’s ongoing strength, which is important given the product’s central role in Regeneron’s revenue mix.

Product performance: the core franchises

Dupixent, while part of an external ecosystem (global net sales reported by Sanofi), continues to be the dominant growth engine. The 35% growth to $6.5 billion underscores a durable demand trajectory in atopic dermatitis and related indications, bolstering Regeneron’s top-line resilience even as competition intensifies. EYLEA HD’s U.S. performance—net sales of $699 million, up 62%—illustrates continued demand in the ophthalmology portfolio, while Libtayo’s 51% rise to $550 million signals continued international expansion for the cancer program.

Put differently: Regeneron’s revenue engine isn’t a one-hit wonder. It’s a decently diversified set of franchises that, while anchored by Dupixent, shows meaningful contributions from EYLEA HD and Libtayo. Investors will watch whether this mix can sustain growth as new competitors come online and as the therapeutic landscape evolves.

Strategic moves: a Sanofi collaboration with a longer horizon

The company expanded its collaboration with Sanofi by adding a $1.0 billion up-front payment and signaling potential to receive up to $7.0 billion in future milestones. Crucially, Regeneron noted that the up-front will be recognized as collaboration revenue in Q4 2026, with milestones contributing in the future. This dynamic introduces a revenue recognition element that can alter quarterly reporting cadence and helps the company monetize collaboration upside even as its internal product pipeline matures.

Analysts will want to see how this up-front and milestone framework interacts with earnings quality, gross margins, and operating expense trajectory. The arrangement also broadens optionality around Sanofi’s contribution to future programs and long-acting antibody platforms, which could become more material over time as additional programs mature.

Pipeline and regulatory progress

Beyond the financials, Regeneron highlighted a pipeline of about 50 product candidates advancing through development. The report cites an FDA decision for cemdisiran in generalized myasthenia gravis as “next month,” a regulatory event that could swing sentiment if positive. On Pasatru (garetosmab), FDA approval for FOP marks a meaningful regulatory milestone for a rare-disease indication, potentially signaling Regeneron’s ability to translate niche programs into commercial reality where clinical benefit is clear.

Taken together, the pipeline offers optionality that could complement, or eventually supplant, dependence on Dupixent as a growth engine. The balance between durable Dupixent performance and milestones from newer programs will shape Regeneron’s earnings trajectory over the next several quarters.

Outlook and implications for the sector

The quarterly cadence remains anchored by a few large revenue streams, but the Sanofi collaboration adds a distinct revenue stream that could help smooth quarterly volatility. For sector peers, Regeneron’s Q3 narrative reinforces a broader theme: a robust, diversified growth platform can coexist with a large, high-margin partner-driven collaboration. Analysts will be especially attentive to two areas: whether the cemdisiran timing delivers a beat to expectations and how the upcoming Q4 2026 collaboration revenue contributes to the bottom line in a way that’s distinct from purely product-driven growth.

In the near term, the street will likely scrutinize EPS cadence as the company navigates milestone recognition and potential R&D investment to sustain the pipeline. The revenue forecast for the quarters ahead will hinge on Dupixent’s durability and the pace at which Sanofi-collaboration milestones materialize. For peers, Regeneron’s results may bolster confidence in a model that blends blockbuster franchises with milestone-driven revenue from collaborations—an approach that can help balance risk across portfolios while preserving upside from innovation.

Takeaway: growth engines, collaboration tailwinds, and a measured risk profile

Regeneron’s Q3 2026 results affirm a company with a powerful core and a pipeline that remains promise with a dose of practical execution. The Dupixent-led growth, the durable performance of EYLEA HD and Libtayo, and the Sanofi up-front plus milestone potential create a multi‑track income story. The presence of a clear regulatory near-term event (cemdisiran) and a meaningful FDA milestone for Pasatru adds optionality that could alter the earnings trajectory if executed well.

For investors, REGN’s stock will likely trade on two engines: the reliability of current revenue streams (and the accompanying EPS trajectory) and the optionality embedded in the pipeline and collaboration framework. In a landscape where EPS consensus and revenue forecasts are constantly updated, Regeneron’s quarterly print provides a baseline from which both analysts and peers will test assumptions about growth durability and the monetization of scientific advances.